Trial intelligence / Profile preview

VALIDATE

2011-002268-26Phase 3Completed

Sponsor: University Health Network
Start: Nov 2012
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised trial in human immunodeficiency virus infection (HIV) and Genital Herpes Type 2 (HSV-2) comparing Valacyclovir with Placebo (2 arms). Primary endpoint: Time to primary composite endpoint. Started Nov 2012; status: completed.

Drugs

valaciclovir

Conditions

human immunodeficiency virus infection (HIV)Genital Herpes Type 2 (HSV-2)

Beyond the preview

Go deeper on 2011-002268-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-002268-26.